Astrazeneca Ab

Astra Aktiebolag

Ab Astra

Aktiebolaget Astra

Eva A Trofast

Kjell I Wetterlin

Jan Andersson

Lars-Erik Briggner

Karin Malmqvist-Granlund

Jan W Trofast

Edib Jakupovic

Magnus Olsson

Hans Jagfeldt

Per-Gunnar Nilsson

Kyrre Thalberg

Risto K Virtanen

Gordon Santesson

Katarina Bystrom

Hans J&auml;gf&auml;ldt

Katarina U Bystrom

Hans J&auml;gfeldt

Erik J Falk

A processing method and apparatus are disclosed for processing an inhaler component of a dry powder inhaler so as to remove any electrostatic charge and improve inhaler performance in drug delivery to the respiratory tract. The method includes exposing the inhaler component, while it contains an amount of medicament, to a gas in a chamber at a first predetermined pressure; exposing the inhaler component, in the chamber, to gas at a second pressure greater than the first pressure; and repeating the exposure of the inhaler component to gas at a pressure no greater than the first predetermined pressure.

Dry powder inhaler

The invention relates to a processing method and apparatus, more particularly, to processing a body so as to remove any electrostatic charge and improve inhaler performance in drug delivery to the respiratory tract.

The invention relates to a stable pharmaceutical composition useful in the treatment of respiratory disorders such as asthma, rhinitis and chronic obstructive pulmonary disease (COPD) and a novel micronisation process for manufacturing a stable formulation for formoterol or its enantiomers and a carrier/diluent comprising a carbohydrate such as lactose.

Pharmaceutical composition containing an active ingredient and a micronised carrier/diluent

Inhalable pharmaceutical compositions are provided, for use in the treatment of respiratory disorders such as asthma, rhinitis and chronic obstructive pulmonary disease (COPD). These compositions have high storage stability, and include formoterol and a corticosteroid.

High storage stability inhalable compositions

The invention relates to a stable pharmaceutical composition useful in the treatment of respiratory disorders such as asthma, rhinitis and chronic obstructive pulmonary disease (COPD) and a novel micronization process for manufacturing a stable formulation for formoterol or its enantiomers and a carrier/diluent comprising a carbohydrate such as lactose.

Process for preparing a pharmaceutical composition containing an active ingredient and a micronised carrier/diluent

There is described a solid particulate pharmaceutical formulation suitable for application to the nose comprising finely divided additive particles and finely divided drug particles, wherein the mass median diameter of the drug particles is greater than that of the additive particles.

Dry powder pharmaceutical formulation

System for dispensing pharmaceutical active compounds

System for dispensing pharmaceutically active compounds

A system for dispensing a clinically effective dose of an inhalable, pharmaceutically active compound, which system includes a dry powder inhaler device containing a powder containing the pharmaceutically active compound, wherein (a) of the powder particles dispensed by the inhaler device (the 'metered DPI dose'), at least 40% are less than about 10 microns in diameter at the point the particles exit the inhaler, (b) the metered DPI dose is sufficient to produce a clinically effective result in a patient; and (c) the amount of the compound in the metered DPI dose is not more than 70% of the minimal amount of the compound which, when dispensed in a pressurized metered dose inhaler, produces an equivalent clinically effective result in the same patient.

There are described finely divided particles of a pharmaceutical substance, wherein the substance when submitted to water vapor gives off heat of less than 1.2 Joules per gram, processes for their production and pharmaceutical formulations containing them.

Pharmaceutical formulation

Process for conditioning substances

A method is provided for dispensing a clinically effective dose of an inhalable, pharmaceutically active compound. The method includes providing a dry powder inhaler containing a powder including the pharmaceutically active compound, and administering to a patient a dose of the compound that is less than 70% of the dose that would be necessary to obtain a physiologically equivalent result were the compound administered by a pressurized metered dose inhaler. The pharmaceutically active compound is in the form of primary particles at least 80% of which have a particle size of less than 10 microns, and the primary particles are provided as agglomerates which are deagglomerated during inhalation so that at least 40% of the dose administered is in the form of primary particles.

The present invention relates to a process for providing a stable crystallinic form to a fine-grained substance or a substance mixture, which can be produced, stored and used while maintaining the aerodynamic properties required for inhalation of such a substance or a substance mixture, by

Micro formoterol particles

A process for providing water-soluble micronized pharmaceutically acceptable inhalable substances, which can be produced, stored and used while maintaining the aerodynamic properties required for inhalation of the pharmaceutically acceptable substances. This process is carried out by the steps of reducing, if necessary, the residual water from the micronized substance by drying at an elevated temperature and/or vacuum; conditioning the dried, micronized pharmaceutically acceptable inhalable substances with a solvent; and eliminating residual solvent by storing under dry conditions as, e.g., in a vacuum or by purging with a dry, inert gas.

Growing community of inventors

Lund, Sweden

Eva A Trofast